OmeCare: Pathway Genomics Investor Says Board Ignored Assets Raid
A Curacao-based investor has hit ex-board members of defunct biotech company Pathway Genomics with a derivative shareholder suit in Delaware's Chancery Court that claims they turned a blind eye to a Ukrainian businessman's scheme to raid and transfer assets to another company, leaving shareholders with nothing.
Read full article »
CEO
Pathway Genomics provides physicians with genetic testing reports on diet, exercise, drug response, carrier status and health conditions.
Read more